Biomea Fusion, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BMEA Nasdaq 2834 biomeafusion.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biomea Fusion, Inc.

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies - Mar 31st, 2026 5:00 am
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts - Mar 30th, 2026 3:03 pm
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes - Mar 30th, 2026 12:24 pm
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth? - Mar 27th, 2026 4:26 am
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results - Mar 25th, 2026 1:32 pm
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights - Mar 24th, 2026 2:05 pm
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - Mar 14th, 2026 2:30 am
Biomea Fusion Details Diabetes, Obesity Pipeline at Citizens Conference, Sees Cash Runway to Q1 2027 - Mar 13th, 2026 1:28 am
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf. - Feb 26th, 2026 9:14 pm
Biomea Fusion to Participate at Upcoming Investor Conferences - Feb 19th, 2026 5:00 am
Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38% - Jan 24th, 2026 6:09 am
Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price Target - Jan 19th, 2026 6:01 am
Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones - Jan 15th, 2026 6:48 am
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones - Jan 12th, 2026 6:00 am
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference - Dec 17th, 2025 5:00 am
Insider Spends US$99k Buying More Shares In Biomea Fusion - Dec 11th, 2025 4:00 am
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - Dec 9th, 2025 4:35 pm
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - Dec 5th, 2025 5:00 am
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - Dec 1st, 2025 2:10 pm
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Dec 1st, 2025 2:05 pm